arrow
A

Arnaud Jaccard

centre de reference nationale pour l'amylose
H指数:60
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Liver stiffness in AL amyloidosis: interest in diagnosis and prognosis

AL淀粉样变性中的肝硬度:其在诊断和预后中的意义

2026-09-060
PRE
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis

Daratumumab-硼替佐米-环磷酰胺-地塞米松治疗新诊断的淀粉样变性: 仙女座最终生存分析

Blood
IF23.1
2026-05-140
OAAI
Health-Related Quality of Life and Mental Health in Autoimmune Thrombotic Thrombocytopenic Purpura Patients in the Caplacizumab Era

与自身免疫性血栓性血小板减少性紫癜患者相关的生命质量及心理健康——卡普拉昔珠单抗时代的现状

2025-12-090
OAAI
The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network

医疗淀粉样变性欧洲登记系统(HEAR):一项具有欧洲扩展策略的国家登记系统设计,以及F-CRIN GRACE网络的建立

2025-10-280
OAAI
Revisiting proliferative glomerulonephritis with monoclonal immunoglobulin deposits through immunoglobulin repertoire sequencing

通过免疫球蛋白序列库测序重新审视伴单克隆免疫球蛋白沉积的增生性肾小球肾炎

2025-09-240
PRE
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

抗PD1疗法在结外NK/T细胞淋巴瘤中的疗效:一项来自LYSA的匹配队列分析

2025-01-200
OA
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study
2024-11-140
OAAI
APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities

APR-246通过靶向代谢细胞易损性克服淋巴恶性肿瘤中天冬酰胺酶的耐药性

BLOOD
IF23.1
2024-11-050
PRE
Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets
2024-10-220
OAAI
Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
2024-04-242
PRE
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
LEUKEMIA
IF13.4
2023-05-088
OAAI
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
2023-01-2524
OAAI
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
2022-09-2912
OAAI
Mass spectrometry-based proteomics in clinical practice amyloid typing: state-of-the-art from a French nationwide cohort
2022-08-0411
OAAI